PARP抑制剂治疗胶质基因突变（GBM）还有多远？

2. Stupp R, Mason WP, van den Bent MJ, et al.; European organization for research and treatment of cancer brain tumor and radiotherapy groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.

3. Jue TR, Nozue K, Lester AJ, et al. Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma. J Transl Med. 2017;15(1):61.

4. Mehta MP, Wang D, Wang F, et al. Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. J Neurooncol. 2015;122(2):409–417.

5. Kleinberg L, Supko JG, Mikkelsen T, et al. Phase I adult brain tumor consortium trial of ABT-888 (veliparib), temozolomide, and radiotherapy for newly diagnosed glioblastoma multiforme including pharmacokinetic data. J Clin Oncol. 2013;31(15 suppl):2065.

6. Taphoorn MJ, Henriksson R, Bottomley A, et al. Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. J Clin Oncol. 2015;33(19):2166–2175.

7. Mansouri A, Hachem LD, Mansouri S, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol. 2019;21(2):167–178.

声明：本的资讯之中相关的信息请注意，请遵从精神科或其他医疗卫生专业人士的看法或指导。